DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Nash P, Kirkham B, Okada M. et al.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Lancet 2017;
389: 2317-2327
We do not assume any responsibility for the contents of the web pages of other providers.